Oregon’s Democratic Party Endorses Legalization of Psilocybin

Lower Doses of Psilocybin May Still Have Antidepressant Effects

Psilocybin taken at low doses could have powerful antidepressant effects, according to new research findings.
GH Research Raises $125 Million to Fund DMT Treatment for Depression

GH Research Raises $125 Million to Fund DMT Treatment for Depression

GH Research closed a $125 million Series B financing round to fund the advancement of its 5-MeO-DMT treatment.
Jewish Psychedelic Summit

First-Ever Jewish Psychedelic Summit Planned for May 2-3

The first conference of its kind, the Jewish Psychedelic Summit, will explore the connection between psychedelics and Judaism.
psychedelic mushrooms

Silo Wellness Expands Shareholder Base to Europe

Toronto's Silo Wellness is now trading on the German Stock Exchange as demand for psychedelic treatments expands.

The Spotlight Round Up Video, April 14th

In this week’s episode of The Spotlight Roundup, we check in with the Fireside Project, the first-ever 24/7 psychedelic peer support line; the State of Oregon forms an advisory board to oversee the implementation of psilocybin use in specialized clinics; and The American Journal of Psychiatry publishes new guidance on how to safety and effectively use Ketamine and Esketamine.

Daniel Carcillo’s Psychedelic Startup Wesana Health Raises More Funds, On Track to Go Public

,
Former NHL player Daniel Carcillo's psychedelic startup Wesana Health is preparing to take the company public.
Ketamine Therapy Shows Benefits in Treating Depression Related to Childhood Abuse

Ketamine Therapy Shows Benefits in Treating Depression Related to Childhood Abuse

,
Adults with depression who were abused or neglected as children responded better to intravenous ketamine therapy than depressed adults who were not mistreated, according to a poster presentation and discussion at the recent Anxiety and Depression…
Psychedelics Company Atai Adds Brain-Computer Interface for Mental Health Treatment

Psychedelics Company Atai Adds Brain-Computer Interface for Mental Health Treatment

Atai Life Sciences is working to combine psychedelics with brain-computer interfaces for mental health treatment.

BIG MindMed MDMA Trial, Atai to Compete with Elon’s Neuralink ? (+ Updates on CMPS, MYCO and ENBI)

Hey Psychedelic Investors! There's been so much news this week that we decided to split "This Week In Psychedelic Stocks" in 2 parts. Part Deux: " BIG MindMed MDMA Trial, Atai's to Compete with Tesla's Neuralink (+Updates on CMPS, MYCO and ENBI)" might be a lot more interesting to some of you, however, I would suggest you watch Part I entitled: "HUGE Studies Released: Psychedelics About to TAKE OVER the Stock market?" That is if you are interested in the general developments in the psychedelic industry for this week. In this episode, there's lots of news for the psychedelic industry writ large. We'll start up with three different studies that were released in the first week of April. 1. We'll cover some MindMed News [ MMED / MMEDF recently announced a new MDMA study ] 2. Atai Life Sciences' Computer Brain Interface & their clinical trial to treat Schizophrenia 3. Compass Pathways (CMPS) has amazing new price targets 4. Mydecine (MYCO / MYCOF ) has progressed four new compounds towards clinical trials 5. Entheon's (ENBI / ENTBF) new Genetic Test Kit Updates ​... ​Timestamps: 0:00​ - Intro 1:47 - MindMed's (MMED / MMEDF / MMQ) Announcing New Data on Personalized MDMA Dosing 6:08 - Atai Life Sciences acquires Psyber Inc to develop Brain Computer Interface -enabled digital therapeutics targeting mental health disorder 8:00 - Atai's Subsidiary, Recognify Life Sciences, to Commence Phase 2 clinical study in Cognitive Impairment associated with Schizophrenia 9:07 - Roth Capital Upgrades Compass Pathways (CMPS) price targets & CMPS has scheduled a corporate update 10:32 - Mydecine ( MYCOF / MYCO ) Announces Four New Lead Drug Candidates for Pre-IND Meetings with the FDA & Health Canada to prepare for clinical trials. ( MYCO 001, MYCO 002, MYCO 003 & MYCO 004 ) 13:02 - Entheon Biomedical (ENBI / ENTBF ) has now launched Halugen's Psychedelics' Genetic KIT So that's it for This Week in Psychedelic Stocks fellow psychedelic investors! I hope you guys found some value in this! As our thumbnail titles states: The SHROOM BOOM is REAL! Psychedelics are taking the world by storm and psychedelic inspired companies are releasing news every single day. We'll try to cover most of them but if there's a company you want us to cover more in debt, please let us know in the comments and we'll try to satisfy your demands. Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! 🙌 Instagram: @psychedelicinvestor Facebook: @thepsychedelicinvestor If you want to collaborate shoot us an email at: thepsychedelicinvestor@gmail.com Music: www.bensound.com https://benzinga.grsm.io/jameshallifa ​... ​ https://benzinga.grsm.io/thepsychedel DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. #MindMed​​​​ ​#MMEDStock #CMPS Stock

HUGE Studies Released: Psychedelics About to TAKE OVER the Stock market? [ +Horizons ETF UPDATE]

Hey Psychedelic Investors! There's been so much news this week that we decided to split "This Week In Psychedelic Stocks" in 2 parts. This segment is entitled "HUGE Studies Released: Psychedelics About to TAKE OVER the Stock market?" for a reason. The News we present will have major implications Psychedelic Stocks like MindMed (MMED /MMEDF/ MMQ), Compass Pathways (CMPS) and more. In this episode, there's lots of news for the psychedelic industry writ large. We'll start up with three different studies that were released in the first week of April. 1. The Effects of Treating Depression with Psilocybin 2. Taking Psychedelics in a Ritual Setting 3. Microdosing study After covering the pertinent aspects of these studies, we'll take a look at Americans' ability to buy Horizons' ETF and finally we'll give you some updates on some decriminalization efforts. So that's it for This Week in Psychedelic Stocks fellow psychedelic investors! I hope you guys found some value in this and I'll keep you posted for more changes! Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! 🙌 Instagram: @psychedelicinvestor Facebook: @thepsychedelicinvestor If you want to collaborate shoot us an email at: thepsychedelicinvestor@gmail.com Music: www.bensound.com https://benzinga.grsm.io/jameshallifa ​... ​ https://benzinga.grsm.io/thepsychedel ​... ​Timestamps: 0:00​ - Intro 1:24 - Effects of Treating Depression with Psilocybin 4:03 - Effects of Taking Psychedelics in A Ritual Setting 7:23 - Exploring the relationship between microdosing, personality & emotional insight 9:36 - Americans May be able to invest in Horizon's ETF 11:42 - Progress on California's bill that would LEGALIZE Possession of Psychedelics 12:57 - Massachusetts Approves Psychedelics Decimalization General thoughts. We've been covering decriminalization and legalization efforts for almost two months now and EVERY WEEK, we see a new state or city starting to understand that psychedelics may be beneficial to society and may be able to treat mental illnesses such as depression, anxiety, ADHD, etc. On top of that, every week, we see study after study releasing promising results on the benefits of psychedelics to treat such mental maladies. If this is not proof that the SHROOM BOOM is real, what is? As more studies are released, it'll only become more clear that psychedelics such as psilocybin, MDMA, DMT, LSD, etc may be able to disrupt a TRILLION dollar industry and us psychedelic investors might as well extract two-fold benefits : a. getting massive returns on investment and b. contributing to make the world a better place. DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. #MindMed​​​​ ​#psychedelics​​​​ #shroomboom